Who are Placebo to salbutamol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ventolin®, ProAir Digihaler, Proventil® HFA, Albuterol/salbutamol MDIs, ProAir® HFA, Albuterol/salbutamol MDI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-salbutamol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to salbutamol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to salbutamol (Placebo to salbutamol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Short-acting beta-2 agonist (SABA). Area: Respiratory.

phase 3 Short-acting beta-2 agonist (SABA) Beta-2 adrenergic receptor (ADRB2) Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to salbutamol (Placebo to salbutamol) — Novartis. Salbutamol is a beta-2 adrenergic agonist that relaxes airway smooth muscle by activating beta-2 receptors, causing bronchodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to salbutamol TARGET	Placebo to salbutamol	Novartis	phase 3	Short-acting beta-2 agonist (SABA)	Beta-2 adrenergic receptor (ADRB2)
Ventolin®	Ventolin®	AstraZeneca	marketed	Short-acting beta-2 agonist (SABA)	Beta-2 adrenergic receptor
ProAir Digihaler	ProAir Digihaler	Pulmonary Research Institute of Southeast Michigan	marketed	Short-acting beta-2 agonist (SABA)	Beta-2 adrenergic receptor
Proventil® HFA	Proventil® HFA	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Short-acting beta-2 agonist (SABA)	Beta-2 adrenergic receptor
Albuterol/salbutamol MDIs	Albuterol/salbutamol MDIs	GlaxoSmithKline	marketed	Short-acting beta-2 agonist (SABA)	Beta-2 adrenergic receptor
ProAir® HFA	ProAir® HFA	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Short-acting beta-2 agonist (SABA)	Beta-2 adrenergic receptor
Albuterol/salbutamol MDI	Albuterol/salbutamol MDI	GlaxoSmithKline	marketed	Short-acting beta-2 agonist (SABA)	Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Short-acting beta-2 agonist (SABA) class)

GlaxoSmithKline · 3 drugs in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
AstraZeneca · 1 drug in this class
Novartis · 1 drug in this class
Pulmonary Research Institute of Southeast Michigan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to salbutamol — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-salbutamol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab